CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 85 enrolled
Drug / intervention
Relacorilant with nab-paclitaxeldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02762981
NCT02762981Phase 2Completed
CompareCT.gov

Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors

Corcept Therapeutics·interventional·Posted May 5, 2016·Updated Dec 6, 2022

In Brief

A Phase 2 clinical trial evaluating Relacorilant with nab-paclitaxel for Solid Tumors. Completed, enrolled 85 participants across 4 sites.

Detailed Summary

The purpose of this study was to assess the safety of the combination of relacorilant (CORT125134), a novel glucocorticoid receptor (GR) antagonist, and nab- paclitaxel in participants with solid tumors and to determine the preliminary efficacy of the combination of relacorilant and nab-paclitaxel. The structure for the study was a single arm, non-randomized, open- label, multicenter trial with no control group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 5, 2016
Enrollment StartMay 23, 2016
Primary CompletionMay 12, 2020
Study CompletionSep 12, 2020
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 10.2 years ago

Interventions

Relacorilant with nab-paclitaxeldrug

Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.